NCT04696692Completed
Single-Cell Map of Immune and Lymphoma Cells in B-cell Non-Hodgkin's Lymphoma
Source: ClinicalTrials.gov · Last updated 22 Dec 2025
Brief summary (registry, in English)
This trial is a translational, prospective, open-label, monocentric research. The study will be conducted in a population of 60 patients with diffuse large B-cell lymphoma (DLBCL) for whom first-line treatment with R-CHOP is planned as part of their standard of care. SIMILY program aims at identifying biomarkers and/or molecular signatures related to immuno-phenotypic and -genotypic characteristics of the tumor and immune microenvironment, at the time of diagnosis, during R-CHOP, and at 24 months or time of progression. Each patient will be followed during 2 years.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 60 (actual)
- First submitted
- 4 Jan 2021
- Start date
- 9 Feb 2021
- Primary completion date
- 11 Dec 2025
- Lead sponsor
- Institut Claudius Regaud
- Diseases
- Diffuse large B-cell lymphoma
- NCT number
- NCT04696692
What you commit to
- Study type: Interventional
- Participants enrolled: 60
- From 9 Feb 2021 to the primary completion date, 11 Dec 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Any condition contraindicated with tumor / blood sampling procedures required by the protocol
- Known history of positive test for Hepatitis B virus or Hepatitis C virus or Immunodeficiency Virus (HIV) or known acquired immunodeficiency syndrome (AIDS)
- Any current severe or uncontrolled disease, including, but not limited to ongoing or active infection and auto immune disorders
Other
- Patient pregnant, or breast-feeding
- Central Nervous System (CNS) involvement
- Any psychological, familial, geographic or social situation, according to the judgment of investigator, potentially preventing the provision of informed consent or compliance to study procedure
- Patient who has forfeited his/her freedom by administrative or legal award or who is under legal protection (curatorship and guardianship, protection of justice)
- Current participation in any other therapeutic clinical study
Who the study is looking for
- Patient with histologically confirmed diffuse large B-cell lymphoma with a planned first line treatment by R-CHOP (treatment by R-CHOP should not have been initiated prior to inclusion in the study)
- Age 18 to 80 years at the time of study entry
- Archived initial diagnostic tumor specimen available
- Life expectancy ≥ 3months
- ECOG Performance status 0-2
- FDG-avid disease (for PET monitoring)
- Signed written informed consent
- Patient able to participate and willing to give informed consent prior performance of any study-related procedures and to comply with the study protocol
- Patient affiliated to a Social Health Insurance in France
Age in the registry: 18 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Institut Universitaire du Cancer Toulouse - Oncopole Coordinator of this site? Confirm its status | Toulouse | France | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.